Drug Combination Details
| General Information of the Combination (ID: C56091) | |||||
|---|---|---|---|---|---|
| Name | Paclitaxel NP Info | + | Bcl-2 siRNA Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Brain cancer
[ICD-11: 2A00]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | U-138MG | CVCL_0020 | Astrocytoma | Homo sapiens | ||
| U-251MG | CVCL_0021 | Astrocytoma | Homo sapiens | |||
| Experimental
Result(s) |
A low dose of taxol in combination with a plasmid vector expressing Bcl-2 siRNA effectively induces apoptosis in glioblastoma cells, markedly decreases tumour cell invasion, completely inhibits in vivo angiogenesis, and remarkably suppresses both intracranial and subcutaneous tumour growth in nude mice. | |||||